multi epitope folate receptor alpha peptide vaccine

Drug Overview

The multi epitope folate receptor alpha peptide vaccine is an advanced immunotherapy designed to help the body fight specific types of cancer. It is not a traditional vaccine used to prevent an infection. Instead, it is a “Smart Drug” known as a therapeutic cancer vaccine. It works by teaching the patient’s own immune system to recognize and attack tumor cells that display a specific protein on their surface.

Here are the key details about this agent:

• Generic Name: Multi-Epitope Folate Receptor Alpha Peptide Vaccine (TPIV 200).
• US Brand Names: None yet. It is currently an investigational drug used in clinical trials.
• Drug Class: Immunotherapy / Therapeutic Cancer Vaccine / Peptide Vaccine.
• Route of Administration: Intradermal (into the skin) or subcutaneous (under the skin) injection.
• FDA Approval Status: Currently investigational. It has received “Fast Track” and “Orphan Drug” designations for certain cancers but is not yet approved for general public use.
  
  Discover the multi epitope folate receptor alpha peptide vaccine. Our expert medical team provides compassionate care and advanced oncology therapies.

What Is It and How Does It Work? (Mechanism of Action)

To understand this vaccine, it helps to know how cancer cells hide. Many cancers, such as ovarian and breast cancer, produce high amounts of a protein called Folate Receptor Alpha (FR-alpha). While this protein exists in healthy cells, it is found in much higher concentrations on the surface of tumor cells.

Training the Immune System

This vaccine acts as an “instruction manual” for the immune system. Here is how it works at the molecular level:

1. The Multi-Epitope Advantage: Most vaccines only target one small part of a protein. This vaccine is “multi-epitope,” meaning it contains several different protein fragments (peptides) from the FR-alpha protein. This provides the immune system with multiple “mugshots” of the cancer, making it harder for the tumor to hide.
2. Activating T-Cells: Once injected, the peptides are picked up by specialized “scout” cells called dendritic cells. These scouts travel to the lymph nodes and present the cancer markers to T-cells (the “soldier” cells of the immune system).
3. The Th Response: Specifically, the vaccine is designed to trigger a T-helper (Th1) response. This sends out chemical signals that recruit and activate killer T-cells.
4. Targeted Destruction: These newly trained T-cells circulate through the body. When they find a cell with FR-alpha on its surface, they attach to it and release toxins that destroy the cancer cell while sparing healthy cells that have low levels of the protein.

By using multiple epitopes, the vaccine ensures that if the cancer tries to change its appearance (a process called “immune escape”), the immune system can still recognize it through the other protein fragments.

FDA Approved Clinical Indications

Because this vaccine is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively studied in approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Ovarian Cancer: Specifically for patients in remission to prevent the cancer from returning.
• Triple-Negative Breast Cancer (TNBC): Used to see if it can improve survival in patients with this aggressive form of cancer.
• Endometrial Cancer: Investigated for tumors that show high levels of the folate receptor.
• Solid Tumors: General research for any tumor that tests positive for FR-alpha expression.

Non-oncological Uses:

• There are currently no non-cancer uses for this vaccine being investigated in human trials.

Dosage and Administration Protocols

Because this is an investigational vaccine, the exact dose is determined by the specific clinical trial protocol. It is usually given as a series of injections to “prime” the immune system, followed by “booster” shots.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Since this is a protein-based vaccine and not a chemical drug processed by the liver or kidneys, standard dose adjustments for these conditions are generally not required. However, patients are monitored for overall health and immune status.

Clinical Efficacy and Research Results

Recent clinical studies (between 2020 and 2025) have shown promising results, particularly in patients who have already finished surgery and chemotherapy.

• Immune Response Rates: In Phase 1 and 2 trials, researchers found that over 90 percent of patients developed a strong T-cell response specifically against the folate receptor protein after receiving the full series of injections.
• Prevention of Recurrence: In a study of ovarian cancer patients in first remission, data suggested that those who received the vaccine had a longer “disease-free interval” (time before the cancer returned) compared to historical averages for those on observation alone.
• Stability of Disease: For patients with breast cancer, numerical data from early 2024 reports showed that the vaccine helped maintain “minimal residual disease” status, meaning it kept tiny amounts of remaining cancer from growing into new tumors.
• Long-Term Memory: Clinical data confirms that the immune system “remembers” the folate receptor for several years, providing long-term protection through periodic booster shots.

Safety Profile and Side Effects

The Multi-Epitope Folate Receptor Alpha Peptide Vaccine is generally very well-tolerated. Because it targets the folate receptor specifically, it does not cause the severe hair loss or nausea associated with chemotherapy.

Common Side Effects (greater than 10 percent):

• Injection Site Reactions: Redness, swelling, itching, or a small bump where the needle was placed.
• Fatigue: Mild tiredness for 24 to 48 hours after the injection.
• Flu-like Symptoms: Low-grade fever, muscle aches, or chills as the immune system “wakes up.”

Serious Adverse Events:

• Allergic Reactions (Rare): As with any vaccine, a very small risk of a severe allergic reaction (anaphylaxis) exists.
• Autoimmune Response: A theoretical risk that the immune system could attack healthy organs that have small amounts of FR-alpha, though this has rarely been observed in trials.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent.

Management Strategies:

• For Injection Pain: Over-the-counter pain relievers like acetaminophen or ibuprofen are usually sufficient.
• Site Care: A cold compress can be applied to the injection site if swelling occurs.
• Observation: Patients are typically asked to wait in the clinic for 30 minutes after the injection to ensure no immediate allergic reactions occur.

Connection to Stem Cell and Regenerative Medicine

This vaccine is currently being explored as part of “Combination Immunotherapy” research.

Scientists are investigating whether this vaccine can be used alongside Stem Cell Transplants in blood and solid tumors. The goal is to “program” the new immune system growing from the stem cells to immediately hunt for FR-alpha.

Additionally, in the field of Regenerative Medicine, researchers are looking at the Folate Receptor’s role in cell growth. By understanding how the vaccine interacts with this receptor, they hope to design better ways to protect healthy stem cell “niches” while the immune system clears out cancer cells.

Patient Management and Practical Recommendations

To ensure the best response to the vaccine, patients should follow specific guidelines.

Pre-treatment Tests to be Performed:

• Tumor Biopsy Testing: Your doctor must confirm that your tumor “expresses” (shows) the Folate Receptor Alpha protein. If it does not, the vaccine will not work.
• Blood Counts: A baseline check of your white blood cell count to ensure your immune system is strong enough to respond.

Precautions During Treatment:

• Steroid Use: You should tell your doctor if you are taking high doses of steroids (like prednisone). Steroids can “quiet” the immune system and make the vaccine less effective.
• Immune Status: If you develop a high fever or an infection between doses, your injection may be delayed until you are healthy.

“Do’s and Don’ts” List:

• DO stay hydrated and rest on the day of your injection.
• DO keep the injection site clean and dry for at least 24 hours.
• DON’T skip scheduled doses or boosters; the “training” of your immune system requires consistency.
• DON’T apply medicated creams or ointments to the injection site unless told by your medical team.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. The Multi-Epitope Folate Receptor Alpha Peptide Vaccine is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.